Abstract
Objective: To evaluate the therapeutic efficacy of a steroid switch from prednisone to dexamethasone in Asians with metastatic castration-resistant prostate cancer (mCRPC) that progressed after docetaxel chemotherapy. Methods: This study included postdocetaxel patients with mCRPC treated with abiraterone acetate combined with prednisone (AA + P) who had experienced prostate-specific antigen (PSA) progression. All patients underwent a steroid switch from prednisone (10 mg/day) to dexamethasone (1 mg/day). The PSA level and clinical symptoms were recorded. Moreover, follow-up was conducted until patients were either lost to follow-up or death. Results: This study included 11 patients from a single center in Taiwan. The median follow-up time starting from AA + P treatment was 19.47 months. Seven patients (63.64%) had >30% PSA decline, and 6 patients (54.55%) had >50% PSA decline. The median percentage of PSA decline was 83.6%. The median time until PSA progression after the steroid switch was 11.38 months. No adverse events greater than grade 3 were noted. Conclusions: Steroid switching is a feasible and effective therapy in docetaxel-treated Asian patients with mCRPC.
References
1.
Cornford
P
, Bellmunt
J
, Bolla
M
, Briers
E
, De Santis
M
, Gross
T
, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer
. Eur Urol
. 2017
;71
(4
):630
–42
. 2.
Chandrasekar
T
, Yang
JC
, Gao
AC
, Evans
CP
. Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
. Transl Androl Urol
. 2015
;4
(3
):365
–680
. 3.
Schweizer
MT
, Antonarakis
ES
. Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born
. Ther Adv Urol
. 2012
;4
(4
):167
–78
. 4.
Auchus
RJ
, Yu
MK
, Nguyen
S
, Mundle
SD
. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer
. Oncologist
. 2014
;19
(12
):1231
–40
. 5.
Fizazi
K
, Scher
HI
, Molina
A
, Logothetis
CJ
, Chi
KN
, Jones
RJ
, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
. Lancet Oncol
. 2012
;13
(10
):983
–92
. 6.
Ryan
CJ
, Smith
MR
, Fizazi
K
, Saad
F
, Mulders
PF
, Sternberg
CN
, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
. Lancet Oncol
. 2015
;16
(2
):152
–60
. 7.
Venkitaraman
R
, Lorente
D
, Murthy
V
, Thomas
K
, Parker
L
, Ahiabor
R
, et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer
. Eur Urol
. 2015
;67
(4
):673
–9
. 8.
Roviello
G
, Sobhani
N
, Corona
SP
, D’Angelo
A
. Corticosteroid switch after progression on abiraterone acetate plus prednisone
. Int J Clin Oncol
. 2020
;25
(2
):240
–6
. 9.
Lorente
D
, Omlin
A
, Ferraldeschi
R
, Pezaro
C
, Perez
R
, Mateo
J
, et al. Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone
. Br J Cancer
. 2014
;111
(12
):2248
–53
. 10.
Fenioux
C
, Louvet
C
, Charton
E
, Rozet
F
, Ropert
S
, Prapotnich
D
, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer
. BJU Int
. 2019
;123
(2
):300
–6
. 11.
Romero-Laorden
N
, Lozano
R
, Jayaram
A
, López-Campos
F
, Saez
MI
, Montesa
A
, et al. Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
. Br J Cancer
. 2018
;119
(9
):1052
–9
. 12.
Kato
T
, Kojima
S
, Fujimoto
A
, Otsuka
K
, Suyama
T
, Hou
K
, et al. PSA response following the ‘steroid switch’ in patients with castration-resistant prostate cancer treated with abiraterone: a case report
. Oncol Lett.
2018
;16
(4
):5383
–8
.13.
Ha Chung
B
, Horie
S
, Chiong
E
. The incidence, mortality, and risk factors of prostate cancer in Asian men
. Prostate Int
. 2019
;7
(1
):1
–8
. 14.
Kaufman
HL
, Andtbacka
RHI
, Collichio
FA
, Wolf
M
, Zhao
Z
, Shilkrut
M
, et al. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
. J Immunother Cancer
. 2017
;5
(1
):72
. 15.
Scher
HI
, Halabi
S
, Tannock
I
, Morris
M
, Sternberg
CN
, Carducci
MA
, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
. J Clin Oncol
. 2008
;26
(7
):1148
–59
. 16.
Holder
SL
, Drabick
J
, Zhu
J
, Joshi
M
. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer
. Cancer Biol Ther
. 2015
;16
(2
):207
–9
. 17.
Marzec
J
, Mao
X
, Li
M
, Wang
M
, Feng
N
, Gou
X
, et al. A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population
. Oncotarget
. 2016
;7
(16
):21393
–403
. 18.
Mao
X
, Yu
Y
, Boyd
LK
, Ren
G
, Lin
D
, Chaplin
T
, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis
. Cancer Res
. 2010
;70
(13
):5207
–12
. 19.
Attard
G
, Merseburger
AS
, Arlt
W
, Sternberg
CN
, Feyerabend
S
, Berruti
A
, et al. Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer
. JAMA Oncol
. 2019
;5
(8
):1159
–67
. © 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
